29 June 2021 – Destiny Pharma to present at Shares & AJ Bell Webinar – 6th July 2021

Destiny Pharma plc

(“Destiny Pharma” or “the Company”)

Destiny Pharma to present at the Shares and AJ Bell Investor
Webinar on 06 July 2021

Brighton, United Kingdom – 29 June 2021 – Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, is pleased to announce that its Chief Executive Officer, Neil Clark, will provide a live presentation on the Company at the Shares and AJ Bell Investor Evening Webinar on Tuesday, 06 July at 6:00 pm BST.

The Shares and AJ Bell Investor Evening Webinar is an opportunity for existing and potential investors to receive a business update from senior executives of listed PLCs.

Attendees will have the opportunity to ask questions to the presenters via an online chat window during the webinar.

Shareholders and potential investors can register to join the webinar for free at:
https://www.sharesmagazine.co.uk/events/event/shares-investor-evening–webinar-060721

-ENDS-

For further information, please contact:

Destiny Pharma plc
Neil Clark, CEO
Shaun Claydon, CFO
+44 (0) 1273 704 440
pressoffice@destinypharma.com

Optimum Strategic Communications
Mary Clark/ Hollie Vile/ Manel Mateus
+44 (0) 203 174 1789
destinypharma@optimumcomms.com

About Destiny Pharma plc
Destiny Pharma is a UK based, clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence, which is the leading cause of hospital acquired infection in the US, and also XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of postsurgical staphylococcal hospital infections including MRSA. It is also codeveloping
SPOR-COV, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections, and has earlier grant funded XF research projects.

For further information on the company, please visit https://www.destinypharma.com

10 June 2021 – XF-73 data abstract to be presented at 2021 ECCMID

Destiny Pharma plc
(“Destiny Pharma” or “the Company”)

Data to be presented from the successful Phase 2b clinical study of XF-73 nasal gel at the prestigious 2021 ECCMID congress

  • XF-73 met its primary end point with >99% nasal aureus reduction within 24 hours
  • Excellent clinical safety profile for XF-73 dosed in patients scheduled for cardiac surgery
  • Infection prevention expert, Professor Julie Mangino MD to present XF-73 data abstract

Brighton, United Kingdom – 10th June 2021 – Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines to prevent life-threatening infections, today announces that an abstract providing analysis and discussion of the late-breaking data arising from the recently completed Phase 2b clinical study of  XF-73 nasal gel has been accepted for presentation at Europe’s premier antimicrobials congress, the 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), to be held 9 – 12 July, 2021.

Presentation Title: Repeated doses of exeporfinium chloride (XF-73) nasal gel over 24 hours significantly reduced the burden of Staphylococcus aureus nasal carriage in at-risk surgical patients: preliminary results from a Phase 2 study. The presentation will update the audience on the following highlights:

  • Met primary endpoint: XF-73 reduced the mean nasal burden of S. aureus in patients undergoing open heart surgery by 2.5 log (CFU/ml) in the 24 hours immediately before surgery a highly statistically significant result, (p<0.0001). This equates to a 99.5% reduction in S. aureus bacterial nasal carriage, which is a very effective reduction by accepted clinical measures.
  • XF-73 showed 2.1 log, (>99%), greater reduction than placebo in the same patient population and this difference in reduction of nasal burden of S. aureus was highly statistically significant (p<0.0001). The effect was maintained during surgery, considered the period when the risk for infections is the highest.
  • These positive results were achieved with just three doses of 0.2% (w/w) XF-73 nasal gel in the 24 hours before incision and the start of surgery.
  • There were no XF-73 nasal gel treatment related adverse events.

Presenting Author:  Julie Mangino MD, FSHEA, FIDSA, Professor Emeritus, Department of Internal Medicine, Division of Infectious Diseases, The Ohio State University College of Medicine, US

Abstract #: 04905

Session: LB: Late breaking clinical trial data

Session code: S182

ECCMID (https://www.eccmid.org/) is the world’s premier Clinical Microbiology & Infectious Diseases event, bringing together experts from many fields to present their latest findings, and developments and share their expertise.

XF-73 is the lead drug candidate from Destiny Pharma’s XF platform, initially being developed for the prevention of post-surgical staphylococcal infections, such as methicillin-resistant Staphylococcus aureus (MRSA), which cause significant complications and increased healthcare costs in the hospital setting. XF-73 has been awarded both Qualified Infectious Disease Product (QIDP) and Fast Track status by the US FDA.

If you would like to meet with Destiny Pharma, please email us on conferences@destinypharma.com

For further information, please contact: 

Destiny Pharma plc
Neil Clark, CEO
Shaun Claydon, CFO
+44 (0) 1273 704 440
pressoffice@destinypharma.com

Optimum Strategic Communications
Mary Clark/ Shabnam Bashir/ Manel Mateus
+44 (0) 203 174 1789
destinypharma@optimumcomms.com

finnCap Ltd (Nominated Advisor & Joint Broker)
Geoff Nash / Kate Bannatyne, Corporate Finance
Alice Lane, Corporate Broking
+44 (0) 20 7220 0500

WG Partners (Joint Broker)
Nigel Barnes / Claes Spång / Nigel Birks
+44 (0) 203 705 9330

About Destiny Pharma plc

Destiny Pharma is a UK based, clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence, which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SPOR-COV, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections, and has earlier grant funded XF research projects.

For further information on the company, please visit  https://www.destinypharma.com

07 June 2021 – Destiny Pharma welcomes G7’s Communique on Antimicrobial Resistance

Destiny Pharma plc
(“Destiny Pharma” or “the Company”)

Destiny Pharma welcomes G7’s Communique on Antimicrobial Resistance

Highlights the global threat of the “silent pandemic” and the urgent need for the development of new treatments

Brighton, United Kingdom – 7th June 2021 – Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, welcomes the G7 Health Ministers’ Meeting communique on 4 June 2021 and its strong message highlighting the global threat of the “silent pandemic” of Antimicrobial Resistance (AMR) and the urgent need for the development of new treatments. Full details are set out at https://www.g7uk.org/g7-health-ministers-meeting-communique-oxford-4-june-2021/

In the announcement the G7 have set out their clear intention to offer increased government support through regulatory frameworks, financial investment and commercial procurement schemes for new medicines that address AMR. They note that the COVID-19 pandemic has “brought into stark focus the impact a novel and initially untreatable infectious disease can have on humanity … [and] highlighted the importance of infection prevention and control measures to tackle AMR.”

Destiny Pharma has been focused for many years on developing novel medicines from its XF platform that specifically address the AMR threat through the XF platform’s unique mechanism of action which can provide safe, effective and fast acting treatments that
do not generate resitance. Its lead programme, XF-73 nasal gel for the decolonisation of patients prior to surgery who are carrying Staphylococcus aureus in the nose, recently delivered excellent Phase 2 data and will now move forward to its final Phase 3 clinical
trials. There are also earlier XF research projects targeted at preventing and/or treating infections whilst also addressing the threat of AMR and not causing the generation of new “superbug” strains.

Destiny Pharma also has a Phase 3 ready clinical programme targeted at preventing the recurrence of gut infections caused by toxic strains of C. difficile infections (CDI). This programme uses a non-toxic strain of C. difficile called NTCD-M3 and has extensive
Phase 2 data showing it to be very effective at reducing the recurrence of CDI and thereby reduces the need for additional treatment with antibiotics. Lower use of antibiotics has the potential to reduce the generation of resistant strains and is in line with G7 and
WHO recommendations.

Neil Clark, CEO of Destiny Pharma, commented:

“We are very pleased that the G7 Health Ministers Meeting has again strongly supported investment, regulatory and commercial incentives for drug developers such as Destiny Pharma. We are working hard to bring new medicines to patients that address the global threat of AMR whilst at the same time delivering cost effective and safe treatments to patients and healthcare practitioners.

Our XF platform has been targeted at the AMR threat for many years and we are very well positioned to rise to the challenge presented by these dangerous pathogens.”

For further information, please contact:

Destiny Pharma plc
Neil Clark, CEO
Shaun Claydon, CFO
+44 (0) 1273 704 440
pressoffice@destinypharma.com

Optimum Strategic Communications
Mary Clark/ Shabnam Bashir/ Manel Mateus
+44 (0) 203 174 1789
destinypharma@optimumcomms.com

finnCap Ltd (Nominated Advisor & Joint Broker)
Geoff Nash / Kate Bannatyne, Corporate Finance
Alice Lane, Corporate Broking
+44 (0) 20 7220 0500

WG Partners (Joint Broker)
Nigel Barnes / Claes Spång / Nigel Birks
+44 (0) 203 705 9330

About Destiny Pharma
Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SPOR-COV, a
novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XFresearch projects.

For further information on the company, please visit https://www.destinypharma.com

03 June 2021 – Result of Annual General Meeting

Destiny Pharma plc
(“Destiny Pharma” or “the Company”)

Result of Annual General Meeting 

Brighton, United Kingdom – 3rd June 2021 – Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, announces that all resolutions proposed to shareholders at the Annual General Meeting held earlier today were duly passed.

The full text of each resolution was included in the notice of the meeting, which was made available on the Company’s website and posted to shareholders on 4th May 2021. The results for the resolutions will shortly be available on the Investors section of the Company’s website, www.destinypharma.com.

Nick Rodgers, Chairman of Destiny Pharma, commented:

“It has been a transformational last six months for Destiny Pharma. We recently delivered excellent Phase 2b data from our XF-73 nasal gel clinical study for the prevention of post-surgical infections and have now started talking to regulators regarding possible Phase 3 clinical plans. Also, we expanded our pipeline through the acquisition of NTCD-M3 to take it through its Phase 3 clinical study. NTCD-M3 has the potential to become the leading treatment for C. difficile infections, targeting a market that is forecast to grow to $1.7 billion by 2026. We remain committed to developing our novel products that prevent infections and look forward to delivering further progress and another successful year.”

For further information, please contact: 

Destiny Pharma plc
Neil Clark, CEO
Shaun Claydon, CFO
+44 (0) 1273 704 440
pressoffice@destinypharma.com 

Optimum Strategic Communications 
Mary Clark/ Shabnam Bashir/ Manel Mateus
+44 (0) 203 174 1789
destinypharma@optimumcomms.com 

finnCap Ltd (Nominated Advisor & Joint Broker)
Geoff Nash / Kate Bannatyne, Corporate Finance
Alice Lane, Corporate Broking
+44 (0) 20 7220 0500

WG Partners (Joint Broker)
Nigel Barnes / Claes Spång / Nigel Birks
+44 (0) 203 705 9330

About Destiny Pharma

Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SPOR-COV, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF research projects. 

For further information on the company, please visit  https://www.destinypharma.com      

02 June 2021 – Positive update on microbiome therapeutic NTCD-M3

Destiny Pharma plc
(“Destiny Pharma” or “the Company”)

Positive update on microbiome therapeutic NTCD-M3 for recurrent C. difficile infections

· Preparations for Phase 3 study progressing to plan
· Established world leading clinical advisory board
· Partnering discussions ongoing

Brighton, United Kingdom – 2nd June 2021 – Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, is pleased to announce positive progress with its lead clinical programme, NTCD-M3.

NTCD-M3 is a novel microbiome therapeutic being developed to reduce the recurrence of C. difficile infections (CDI) in the gut. CDI is the leading cause of hospital acquired infection in the US and current treatments lead to significant recurrence. In the US, there are approximately 500,000 cases of CDI each year; many of these initial cases then recur leading to 29,000 deaths per year.

NTCD-M3 has the potential to become the leading treatment for CDI, as it appears to deliver clear advantages to both existing CDI treatment options and also to those currently in clinical development.

The benefits of NTCD-M3 include:

· Single bacterial strain: a naturally occurring, single strain of a non-toxigenic bacteria
· Good safety: well-defined treatment
· Strong clinical data: CDI recurrence rate for NTCD-M3 treated patients with the best dose in previous Phase 2 trial of only 5% is “class leading”
· Convenient treatment option: can be taken alongside all current standard of care antibiotic treatments as a single capsule taken once daily for seven days
· Well-established manufacturing: will be manufactured at high volume and low cost with a long shelf life which should enable high uptake and a strong pharmacoeconomic position
· Fast Track designation by the FDA

Destiny Pharma is progressing the planning for the single Phase 3 clinical study that needs to be completed before submitting marketing authorisation applications in the US and Europe. The Phase 3 clinical study remains on schedule to commence in 2022.

Key development and manufacturing activities undertaken to date include:

· Completed the technology transfer of information into the new contract drug manufacturing organisation (CDMO) that will produce NTCD-M3 in its specialised biotherapeutic fermentation plant
· Completed the set-up of key analytical viability methods that will be used to assess the quality and purity of the spores of NTCD-M3 produced in the manufacturing process
· Initiated process development work on fermentation to achieve a high and reproducible NTCD-M3 concentration
· Preliminary work underway to define a matrix and method of drying to isolate NTCD-M3 within a solid matrix for formulation as an easy to use, stable, oral capsule

Clinical trial planning is progressing well and activities already underway include:

· Establishment of a NTCD-M3 clinical advisory board consisting of Professor Dale Gerding MD US, who discovered NTCD-M3, Professor Mark Wilcox MD, UK key opinion leader in CDI and other medical and drug development experts with recent experience of running and designing international Phase 3 clinical studies in CDI
· Initiated the supplier selection of a clinical trial organisation (CRO) for the Phase 3 study

Destiny Pharma has also commenced discussions with potential licensing partners and collaborators and is encouraged by the level of interest in the programme. The aim is to secure a partner to help fund the planned Phase 3 clinical study and participate in the future commercial launch of NTCD-M3.

Neil Clark, Chief Executive Officer of Destiny Pharma, commented:

“We have made significant progress since closing the £10.4 million equity funding in December 2020 that enabled the NTCD-M3 acquisition. NTCD-M3 is a potential breakthrough in CDI treatment targeting a market that is forecast to grow to $1.7 billion by 2026 and is a very valuable, late-stage asset. We look forward to making further progress this year and to finalising the Phase 3 study design and manufacturing set up.”

For further information, please contact:

Destiny Pharma plc
Neil Clark, CEO
Shaun Claydon, CFO
+44 (0) 127 370 4440
pressoffice@destinypharma.com

Optimum Strategic Communications
Mary Clark/ Shabnam Bashir/ Manel Mateus
+44 (0) 203 174 1789
destinypharma@optimumcomms.com

finnCap Ltd (Nominated Advisor & Joint Broker)
Geoff Nash / Kate Bannatyne, Corporate Finance
Alice Lane, Corporate Broking
+44 (0) 207 220 0500

WG Partners (Joint Broker)
Nigel Barnes / Claes Spång / Nigel Birks
+44 (0) 203 705 9330

About Destiny Pharma
Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SPOR-COV, a
novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF research projects.

For further information on the company, please visit www.destinypharma.com